Skip to content
PeptideTech
Cart

Home / Research library / Sermorelin

Peptides

Sermorelin: molecular data, studies & sources

Sermorelin is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C149H246N44O42S
Molecular weight (MW)
3357.9 g/mol
PubChem compound ID
16132413
Record title
Sermorelin

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 16132413 · retrieved 2026-09-21

2D molecular structure for Sermorelin, PubChem CID 16132413
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
InChIKey
WGWPRVFKDLAUQJ-MITYVQBRSA-N
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N
Machine-readable PubChem source

Identifiers & sequence

PubChem CID
16132413
CAS Registry Number
86168-78-7via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII
89243S03TE
InChIKey
WGWPRVFKDLAUQJ-MITYVQBRSA-N

Peptide sequence · 29 residues (one-letter code; X marks a residue without a one-letter code)

YADAIFTNSYRKVLGQLSARKLLQDIMSR

Condensed notation with terminal groups and non-standard residues

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.

Calculated molecular descriptors
Monoisotopic (exact) mass3355.8187 Da
Heavy atoms236
Hydrogen-bond donors52
Hydrogen-bond acceptors47
Rotatable bonds115
Topological polar surface area1446.9 Ų
Calculated logP (Crippen)-14.35
Rings3
Stereocenters31
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Sermorelin (listed as sermorelin acetate) was the active ingredient of GEREF (NDA 019863, approved December 28, 1990; NDA 020443, approved September 26, 1997). Drugs@FDA lists both applications as discontinued (checked October 7, 2026). Research-labelled Sermorelin listings are not GEREF and are not FDA-approved drugs.

FDA-approved medicines with the same active ingredient (Drugs@FDA)
MedicineApplicationSponsorFirst approvalMarketing status
GEREFsermorelin acetateNDA 019863EMD SERONODiscontinued
GEREFsermorelin acetateNDA 020443EMD SERONO INCDiscontinued

An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: Same active moiety: the approved products list sermorelin acetate; the research record is sermorelin (PubChem CID 16132413).

Source: Drugs@FDA via openFDA (application records; DailyMed label set IDs) · checked . openFDA data are not intended for clinical decisions.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Sermorelin as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received Sermorelin, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

  1. Human study · PubMed trial index Compound given to participants

    Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.

    Thorner M, Rochiccioli P, Colle M et al. · The Journal of clinical endocrinology and metabolism · 1996

    PMID 8772599 · DOI: 10.1210/jcem.81.3.8772599

  2. Human study · PubMed trial index Compound given to participants

    A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency.

    Chen RG, Shen YN, Yei J et al. · Acta paediatrica (Oslo, Norway : 1992). Supplement · 1993

    PMID 8329830 · DOI: 10.1111/j.1651-2227.1993.tb12834.x

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Research publication · design requires review

    Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

    Walker RF · Clinical interventions in aging · 2006

    PMID 18046908 · DOI: 10.2147/ciia.2006.1.4.307

  2. Research publication · design requires review

    A potentially effective drug for patients with recurrent glioma: sermorelin.

    Chang Y, Huang R, Zhai Y et al. · Annals of translational medicine · 2021

    PMID 33842627 · DOI: 10.21037/atm-20-6561

  3. Research publication · design requires review

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

    Prakash A, Goa KL · BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999

    PMID 18031173 · DOI: 10.2165/00063030-199912020-00007

Sermorelin supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Sermorelin for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
American PeptidesUSD5mg Vial1 recorded offers5mg Vial · $60.00Checked Oct 13, 2026Supplier listing, Sermorelin 5mg Vial, American Peptides, opens in a new tab
Blank PeptidesUSD10mg Vial1 recorded offers10mg Vial · $70.00Stale observation · Checked Sep 30, 2026Supplier listing, Sermorelin 10mg Vial, Blank Peptides, opens in a new tab
Amino ClubUSD10mg Vial1 recorded offers10mg Vial · $59.99Stale observation · Checked Sep 28, 2026Supplier listing, Sermorelin 10mg Vial, Amino Club, opens in a new tab
Nova Peptide SupplyUSD5mg Vial1 recorded offers5mg Vial · $49.99Checked Oct 13, 2026Supplier listing, Sermorelin 5mg Vial, Nova Peptide Supply, opens in a new tab
Amino USAUSD15mg Vial · 2mg Vial2 recorded offers15mg Vial · $100.00Checked Oct 13, 2026Supplier listing, Sermorelin 15mg Vial, Amino USA, opens in a new tab
Cenexa LabsUSD5mg Vial1 recorded offers5mg Vial · $49.99Checked Oct 12, 2026Supplier listing, Sermorelin 5mg Vial, Cenexa Labs, opens in a new tab

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles